NanoSurface Biomedical awarded $1.9M in new funding from the NIH, bringing total non-dilutive NIH funding awarded to NanoSurface to $3.1M.
Read More
NanoSurface Biomedical announced today the launch of the 384-well NanoSurface Plate™, the newest and highest-throughput offering of the NanoSurface Plates™ product line.
Read More
NanoSurface Biomedical announced today that it has acquired Silene Biotech, a Seattle biotechnology company focused on stem cell banking and services. This acquisition expands NanoSurface’s capabilities in developing human stem cell-based platforms and technologies to accelerate the development of new drugs.
Read More